This month, we get to know the Fundació ACE centre behind EPAD. The team of Dr. Mercè Boada (principal investigator of the EPAD project in Fundació ACE) began recruiting in June 2019 and has currently recruited over 60 participants in the EPAD Longitudinal Cohort Study (LCS). We caught up with her team and asked them…
EPAD is pleased to announce the release of a new publication entitled “The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0” in the Journal of Prevention of Alzheimer’s disease. This paper describes the baseline data from the first 500 research participants (V500.0) to assist current and future researchers with their…
The European Prevention of Alzheimer’s Dementia (EPAD), a major Europe-wide initiative aiming to improve the understanding of the early stages of Alzheimer’s disease, has announced the release of its first wave of data as part of its EPAD Longitudinal Cohort Study. The project is one of the world leading dementia prevention studies involving 39 organisations.…
What is your current role in EPAD? I am a project manager for the overall EPAD project. My main role, as member of the EPAD Project Management office (WP5), is to provide overall management to the project including supporting the coordinator in liaising with the Innovative Medicines Initiative (IMI), follow up and management of the…
What is your current role in EPAD? I was the local EPAD Principal Investigator but my neurology colleague Tobias Langheinrich has recently taken over. Greater Manchester is one of the EPAD sites. The Greater Manchester Dementia Research Centre (GMDRC) is a collaboration between the NIHR, Greater Manchester Mental Health Foundation Trust and the University of…
As part of the Clinical Trials Digital Week, KNect365 Life Sciences organised a global 4-day series of live educational webcasts and downloadable resources providing the latest insights into clinical partnerships, outsourcing, operations and technology from 13-16 May 2019. Katrin Haeverans (Clinical Scientist and External Affairs Director at Janssen) was invited to deliver a webinar on…
The European Prevention of Alzheimer’s Dementia (EPAD) project, a highly innovative programme aiming to streamline the testing and development of preventative treatments for Alzheimer’s disease, is very pleased to announce the upcoming release of its first wave of data including the baseline data from the first 500 research participants (V500.0). Researchers will now have access…
Neuronet, a coordination and support action funded by the Innovative Medicines Initiative (IMI), brings together 15 IMI consortium projects working on neurodegenerative disease (such as Alzheimer’s), encompassing over EUR 290 million in research funding. The Neuronet programme held four parallel sessions as part of the Alzheimer Europe conference on 24 and 25 October. This involved…
Lynne Hughes, VP and head of medical CNS strategy at IQVIA, talked about EPAD accomplishments and challenges in an interview article. She provided insights on how EPAD and IQVIA are contributing to advance Alzheimer’s disease research. EPAD is celebrating five years since its inception. What has it accomplished? We have 23 European sites enrolling subjects…
The EPAD project, originally scheduled to end in December 2019, has been extended. We are pleased to share that IMI has officially approved our request for a 6-month no-cost extension to the project, setting the end date in June 2020. This extension will allow the delivery of the start of the first EPAD Proof of…
